Krzysztof Kalwak
Krzysztof Kalwak is an expert in Hematology at 4th Military Clinical Hospital in Wroclaw (Poland). As of October 2026, ScienceLeadR ranks Krzysztof Kalwak in the top 1% of experts worldwide for Stem Cell Transplantation, Cell Transplantation and Leukemia. Krzysztof Kalwak has authored 340 publications, the most recent in 2026, and is an investigator in 12 clinical trials, 7 of them ongoing. SLR score: 1,062 (community average: 125). How the SLR is computed.
LeadR Profile
Hematology
Subspecialties: Transplantation - Oncology - Surgery
Main Topics
Publications and Clinical Studies
Profile data updated on
Expert Rankings
Top experts on the MeSH terms this expert works on
Organizations
Career arc: 1995 - 2026
Number : 340
Citations
Main journals
Best Journals
Breakdown by type
Click a legend label to hide or show it in the chart.
Latest Publications
5 most recent indexed articles
Source: Pubmed
| Title | Journal | Year | Citations |
|---|---|---|---|
| Treatment Outcomes and Prognostic Factors in Children with Myeloid Leukemia Associated with Down Syndrome: A Nationwide Polish Retrospective Study. PMID 42882010 — down syndrome, retrospective studies, leukemia, leukemia, myeloid, therapeutics, prognosis, child | J Clin Med | 2026 | 0 |
| Survival after hematopoietic cell transplantation in children and adults in four decades of experience: nationwide study. PMID 42877690 — cells, immune system diseases, transplants, cell transplantation, transplantation, child, survival rate | Front Immunol | 2026 | 0 |
| Study of Telomere Length Kinetics and Telomerase Reverse Transcriptase Gene Polymorphism in Children Undergoing Allogeneic Haematopoietic Stem Cell Transplantation. PMID 42792944 — cells, genes, genomics, microscopy, electron, scanning transmission, chimerism, telomerase, stem cells, rna-directed dna polymerase, polymorphism, genetic, alleles, transplants, cell transplantation, stem cell transplantation, telomere, transplantation, infections, child | Genes (Basel) | 2026 | 0 |
| Incidence of Veno-Occlusive Disease in Patients with Neuroblastoma Treated with Autologous Stem Cell Transplantation After Chemoimmunotherapy with Temozolomide, Irinotecan, and Dinutuximab Beta. PMID 42794879 — cells, microscopy, electron, scanning transmission, incidence, temozolomide, stem cells, drug therapy, risk factors, therapeutics, cell transplantation, stem cell transplantation, neuroblastoma, transplantation, irinotecan, chemotherapy | Cancers (Basel) | 2026 | 0 |
| Transplant-associated thrombotic microangiopathy in children treated with allogeneic hematopoietic stem cell transplantation. PMID 42768066 — thrombotic microangiopathies, cells, microscopy, electron, scanning transmission, hematopoietic stem cell transplantation, stem cells, transplants, cell transplantation, stem cell transplantation, hematopoietic stem cells, transplantation, child | Bone Marrow Transplant | 2026 | 0 |
Clinical Studies 12
Synthesis
By phase:
By status:
By type:
By Monocentric/Multicentric:
Main Topics
Cohort/Consortium Investigators 1
Ongoing Clinical Trials
7 ongoing trials started since 2021, where this expert is an investigator
Source: ClinicalTrials
| Study | Phase | Status | Start |
|---|---|---|---|
| Trial of efficacy and safety of MC0518 versus best available therapy in patients with steroid refractory acute graft versus host disease 2023-503952-28-00 — cells, safety, microscopy, electron, scanning transmission, stem cells, mesenchymal stem cells, graft vs host disease, transplants, therapeutics, stromal cells, cell transplantation, stem cell transplantation, steroids, transplantation | Phase 2 | Active not recruiting | 2023 |
| Study to evaluate the safety and efficacy of asciminib in pediatric participants with chronic myeloid leukemia 2025-522138-29-00 — safety, leukemia, leukemia, myeloid, leukemia, myelogenous, chronic, bcr-abl positive, mutation | Phase 2 | Recruiting | 2026 |
| Phase III Clinical Trial for CPX 351 in Myeloid Leukemia in Children with Down Syndrome 2018 2022-501457-37-00 — down syndrome, leukemia, leukemia, myeloid, child | Phase 3 | Recruiting | 2021 |
| AIEOP BFM 2017 POLAND Collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia A randomized phase III study conducted in agreement with the AIEOP BFM study group 2024-517253-27-00 — precursor cell lymphoblastic leukemia-lymphoma, genetics, leukemia, adolescent, therapeutics, child | Phase 3 | Active not recruiting | 2021 |
| Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory Relapsed KMT2A r NUP98 r or NPM1 mut Acute Myeloid Leukemia (AML) 2025-521390-14-00 — leukemia, drug therapy, leukemia, myeloid, acute, leukemia, myeloid, therapeutics, chemotherapy | Phase 2 | Not yet recruiting | 2026 |
LeadR Networks
Main global connection map